Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration-Reference-Cited by-同舟云学术

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration

Published:2019-11 Issue:11 Volume:30 Page:1686-1688
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mountzios G.^ORCID,Remon J.,Novello S.,Blais N.,Califano R.,Cufer T.,Dingemans A.M.,Liu S.V.,Peled N.,Pennell N.A.,Reck M.,Rolfo C.,Tan D.,Vansteenkiste J.^ORCID,West H.,Besse B.

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz295/30036491/mdz295.pdf

Reference17 articles.

1. Metastatic non-small cell lung cancer: eSMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann. Oncol,2018

2. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

3. KEYNOTE-189: updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC;Gadgeel;J Clin Oncol,2019